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Introduction
‘Humanity has but three great enemies: 
fever, famine and war; of these by far the greatest, 
by far the most terrible, is fever’ [1].
Fever is one of the cardinal signs of infection and, nearly 
120 years after William Osler’s statement in his address 
to the 47th annual meeting of the American Medical 
Association [1], infectious diseases remain a major cause 
of morbidity and mortality. Despite this, it is unclear 
whether fever itself is truly the enemy or whether, in fact, 
the febrile response represents an important means to 
help the body ﬁ ght infection. Furthermore, it is unclear 
whether the administration of antipyretic medications or 
physical cooling measures to patients with fever and 
infection is beneﬁ cial or harmful [2], [3]. Here, we review 
the biology of fever, the signiﬁ cance of the febrile 
response in animals and humans, and the current 
evidence-base regarding the utility of treating fever in 
intensive care patients with infectious diseases.
The biology of fever
Regulation of normal body temperature
Th ermoregulation is a fundamental homeostatic mecha-
nism that maintains body temperature within a tightly 
regulated range. Th e ability to internally regulate body 
temperature is known as endothermy and is a charac-
teristic of all mammals and birds. Th e thermoregulatory 
system consists of an aﬀ erent sensory limb, a central 
processing center, and an eﬀ erent response limb. In 
humans, the central processing center controlling the 
thermoregulatory set-point is the hypothalamus. Both 
warm-sensitive and cold-sensitive thermoreceptors are 
involved in the aﬀ erent limb. Stimulation of the cold-
sensitive receptors activates eﬀ erent responses relayed 
via the hypothalamus that reduce heat loss and increase 
heat production. Th ese responses include reducing blood 
ﬂ ow to the peripheries and increasing heat production by 
mechanisms including shivering. Conversely, stimulation 
of warm-sensitive receptors ultimately increases heat loss 
through peripheral vasodilation and evaporative cooling 
caused by sweating.
The cellular and molecular basis of the febrile response
Upward adjustment of the normal hypothalamic thermo-
regulatory set-point leading to fever is typically part of a 
cytokine-mediated systemic inﬂ ammatory response 
syndrome that can be triggered by various infectious 
etiologies including bacterial, viral, and parasitic infec-
tions as well as by a range of non-infectious etiologies 
including severe pancreatitis and major surgery.
In patients with sepsis, the febrile response involves 
innate immune system activation via Toll-like receptor 4 
(TLR-4). Th is activation leads to production of pyrogenic 
cytokines including interleukin (IL)-1β, IL-6, and tumor 
necrosis factor (TNF)-α. Th ese pyrogenic cytokines act 
on an area of the brain known as the organum vascu-
losum of the laminae terminalis (OVLT) leading to the 
release of prostaglandin E2 (PGE2) via activation of the 
enzyme cyclo-oxygenase-2 (COX-2). PGE2 binds to 
receptors in the hypothalamus leading to an increase in 
heat production and a decrease in heat loss until the 
temperature in the hypothalamus reaches a new, elevated, 
set-point. Once the new set-point is attained, the 
hypothalamus maintains homeostasis around this new 
set-point by the same mechanisms involved in the 
regulation of normal body temperature. However, in 
addition, there are a number of important speciﬁ c 
negative feedback systems in place that prevent excessive 
elevation of body temperature. One key system is the 
glucocorticoid system, which acts via nuclear 
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factor-kappa B (NF-κB) and activator protein-1 (AP-1). 
Both these mediators have anti-inﬂ ammatory properties 
and downregulate the production of pyrogenic cytokines, 
such as IL-1β, IL-6, and TNF-α. Th e febrile response is 
further modulated by speciﬁ c antipyretic cytokines 
including IL-1 receptor antagonist (IL-1RA), IL-10, and 
TNF-α binding protein.
Heat shock proteins and the febrile response
Th e negative feedback systems outlined above are not the 
only mechanisms that exist to protect cells from being 
damaged by the febrile response. In addition, the heat 
shock proteins (HSPs) provide intrinsic resistance to 
thermal damage. Genes encoding the HSPs probably ﬁ rst 
evolved more than 2.5  billion years ago. Th ey represent 
an important system providing protection to cells, not 
only against extremes of temperature, but also against 
other potentially lethal stresses including toxic chemicals 
and radiation injury. During heat-stress, transcription 
and translation of HSPs is upregulated. HSPs can then 
trigger refolding of heat-damaged proteins preserving 
them until heat-stress has passed or, if necessary, can 
transport denatured proteins to organelles for intra-
cellular degradation. As well as providing protection 
against cellular damage from the thermal stress induced 
by fever, the HSPs may themselves be important 
regulators of the febrile response. For example, HSP  70 
inhibits pyrogenic cytokine production via NF-κB. HSPs 
also inhibit programmed cell death, which might 
otherwise be induced by an invading pathogen.
The physiological consequences of fever
Th e febrile response leads to a marked increase in 
metabolic rate. In humans, generating fever through 
shivering increases the metabolic rate above basal levels 
by six-fold [4]. In critically ill patients with fever, cooling 
reduces oxygen consumption by about 10  % per °C 
decrease in core temperature and signiﬁ cantly reduces 
cardiac output and minute ventilation [5]. Any potential 
beneﬁ t of the febrile response needs to be weighed 
against this substantial metabolic cost.
The immunological consequences of fever
Temperatures in the physiological febrile range stimulate 
the maturation of murine dendritic cells. Th is is 
potentially important because dendritic cells act as the 
key antigen presenting cells in the immune system. 
Human neutrophil cell motility and phagocytosis are 
enhanced by temperatures in the febrile range, and 
growth of intracellular bacteria in human macrophages 
in vitro is reduced by temperatures in the febrile range 
compared to normal temperatures. Murine macrophages 
demonstrate a range of enhanced functions at tempera-
tures in the febrile range. Th ese eﬀ ects include enhanced 
expression of the Fc receptors that are involved in 
mediating antibody responses, and enhanced phago-
cytosis. Temperatures in the physiological febrile range 
enhance binding of human lymphocytes to the vascular 
endothelium. Th is L-selectin-mediated binding is 
important in facilitating lymphocyte migration to sites of 
tissue inﬂ ammation or infection. In mice, T lymphocyte-
mediated killing of virus-infected cells is increased by 
temperatures in the febrile range and helper T-cell 
potentiation of antibody responses is enhanced. In 
contrast to other cells of the immune system, the 
cytotoxic activity of natural killer cells is reduced by 
temperatures in the febrile range compared to normal 
body temperature. Although their functions are 
enhanced by temperatures in the physiological febrile 
range (38–40  °C), neutrophils and macrophages have 
substantially reduced function at temperatures of ≥ 41 °C.
The eff ects of fever on the viability of microbial 
pathogens
Temperatures in the human physiological febrile range 
cause direct inhibition of some viral and bacterial 
organisms such as inﬂ uenza virus [6], Streptococcus 
pneumonia [7], [8], and Neisseria meningitides [9] which 
can all cause life-threatening illnesses. For inﬂ uenza, the 
degree of heat sensitivity appears to be a determinant of 
virulence, such that strains with a shut-oﬀ  temperature of 
≤38  °C cause mild symptoms, whereas strains with a 
shut-oﬀ  temperature of ≥39  °C cause severe symptoms 
[6]. Th e susceptibility of a pathogen to heat may have 
signiﬁ cance in terms of its pathogenicity in a particular 
host. For example, Campylobacter jejuni is not 
pathogenic in birds (body temperature 42  °C) but is 
pathogenic in humans (body temperature 37 °C) and the 
growth and chemotactic ability of C. jejuni in vitro are 
greater at 37 °C than at 42 °C [10].
The signifi cance of fever in animals with infections
Th e febrile response to infection is seen in a range of 
animal species including not only endotherms, such as 
mammals and birds, but also ectotherms, including 
reptiles, amphibians, and ﬁ sh. Th e febrile response can 
be blocked by inhibition of COX in a diverse range of 
species including desert iguanas [11] and bluegill sunﬁ sh 
[12], as well as higher animals like humans. As COX 
catalyzes the generation of prostaglandins from 
arachidonic acid, this suggests that the pivotal role of 
PGE2 in the regulation of the thermostatic set-point may 
be preserved in these species as well as in higher animals. 
Such a common biochemical mechanism to regulate 
fever across such a diverse group of animals raises the 
possibility that the febrile response may have evolved in a 
common ancestor. If this is the case, then fever probably 
emerged as an evolutionary response more than 350 million 
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years ago [13]. As the febrile response comes at a 
signiﬁ cant metabolic cost [4], [5], its persistence across 
such a broad range of species provides strong 
circumstantial evidence that the response has some 
evolutionary advantage. Furthermore, given that the 
response appears ubiquitous, it logically follows that the 
components of the immune system would have evolved 
to function optimally in the physiological febrile range.
In experimental models in mammals, the febrile 
response appears to oﬀ er a survival advantage across a 
range of viral infections. Newborn mice infected with 
coxsackie virus, which are allowed to develop a fever 
have a much lower mortality than mice which are 
prevented from developing a fever [14]. Similarly, 
increasing the environmental temperature from 23–26 °C 
to 38  °C increases the core temperature of Herpes 
simplex-infected mice by about 2  °C and increases their 
survival from 0  % to 85  % [15]. A meta-analysis of the 
eﬀ ect of antipyretic medications on mortality in animal 
models of inﬂ uenza infection demonstrated that 
antipyretic treatment was associated with an increased 
mortality risk [OR 1.34 (95 % CI 1.04-1.73)] [16].
Studies in mammalian models of bacterial infections 
have generally yielded similar results. In rabbits infected 
with Pasteurella multocida, the presence of a mild fever 
of up to 2.25  °C above normal was correlated with the 
greatest chance of survival compared to either 
normothermia or fever of >  2.25  °C above normal [17]. 
Although mice are predominantly endothermic, they 
appear to require external sources of heat to generate a 
fever. If mice are allowed to position themselves in a cage 
with a temperature gradient, they increase their ambient 
temperature preference and elevate their core tempera-
ture by 1.1 °C after a lipopolysaccharide (LPS) challenge 
[18]. Housing mice at 35.5 °C rather than 23 °C increases 
their core body temperature by about 2.5  °C, alters 
cytokine expression, and improves survival in Klebsiella 
pneumoniae peritonitis [19]. In this model, the elevated 
body temperature seen with increased ambient 
temperature was associated with a 100,000-fold 
reduction in the intraperitoneal bacterial load [19]. A 
recently published systematic review and meta-analysis 
of the eﬀ ects of antipyretic medications on mortality in S. 
pneumoniae infection identiﬁ ed four animal studies 
comparing aspirin to placebo and demonstrated that the 
administration of aspirin was associated with an 
increased risk of death [OR 1.97 (95 %CI 1.22-3.19)] [20].
The signifi cance of fever in humans with infection
Fever, hyperthermia, and antipyresis in non-ICU patients 
with infections
Viral infections
Two double blind randomized placebo-controlled trials 
in 45 volunteers inoculated with either rhinovirus type 21 
(study one) or rhinovirus type 25 (study two) demon-
strated that administration of aspirin did not alter the 
proportion of patients who developed clinical illness or 
signiﬁ cantly alter the frequency or severity of symptoms 
[21]. Although the administration of aspirin signiﬁ  cantly 
increased the shedding of rhinovirus in these trials, only 
one of the 45 patients developed fever so this increase in 
shedding was probably not attributable to the antipyretic 
eﬀ ect of aspirin [21]. A similar study of 60 volunteers 
inoculated with rhinovirus and randomized to aspirin, 
paracetamol, ibuprofen, or placebo showed that the use 
of either aspirin or paracetamol was associated with 
suppression of the serum antibody response and a rise in 
circulating monocytes [22]. Th ere were no signiﬁ cant 
diﬀ erences in viral shedding among the four groups. 
However, the subjects treated with aspirin or paracetamol 
had a signiﬁ cant increase in nasal symptoms and signs 
compared to the placebo group [22]. In rhinovirus-
infected volunteers treated with pseudo ephe drine, the 
addition of ibuprofen had no eﬀ ect on symptoms or on 
viral shedding or viral titers [23]. Again, only two of the 
58 subjects developed a fever. A randomized controlled 
trial of children aged six months to six years with 
presumed non-bacterial infection and a fever of ≥ 38 °C 
demonstrated that administration of paracetamol 
increased the children’s activity but not their mood, 
comfort or appetite [24].
Overall, the data from clinical studies in non-ICU 
patients do not support the hypothesis that antipyresis has 
a clinically signiﬁ cant beneﬁ cial or detrimental impact on 
the course or severity of minor viral illnesses. Although 
antipyretic medicines may increase the duration of 
rhinovirus shedding and time until crusting of chicken pox 
lesions, these eﬀ ects seems unlikely to be attributable to 
antipyresis and are of uncertain clinical importance.
Bacterial infections
Th ere are no randomized controlled trial data examining 
strategies of fever management on patient-centered 
outcomes in non-ICU patients with bacterial infections. 
However, there are historical examples of dramatic 
responses to treatment with therapeutic hyperthermia in 
some infectious diseases. It has been known since the 
time of Hippocrates that progressive paralysis due to 
neurosyphilis sometimes resolves after an illness 
associated with high fever. Th is observation led Julius 
Wagner-Jauregg to propose, in 1887, that inoculation of 
malaria might be a justiﬁ able therapy for patients with 
‘progressive paralysis’. His rationale was that one could 
substitute an untreatable condition for a treatable one – 
malaria being treatable with quinine. In 1917, he tested 
his hypothesis in nine patients with paralysis due to 
syphilis by injecting them with blood from patients 
suﬀ ering from malaria. Th ree of the patients had 
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remission of their paralysis. Th is led to further experi-
ments and clinical observations on more than a thousand 
patients with remission occurring in 30  % of patients 
with neurosyphilis-related progressive paralysis ‘treated’ 
with fever induced by malaria compared to spontaneous 
remission rates of only 1  %. Th is work on fever therapy 
led to Julius Wagner-Jauregg being awarded the Nobel 
Prize in Physiology or Medicine in 1927 [25]. Subse-
quently, fever therapy was shown to be eﬀ ective in 
treating gonorrhea. Inducing a hyperthermia of 41.7  °C 
for six hours in the ‘Kettering hypertherm chamber’ led 
to cure in 81 % of cases [26].
A number of observational studies have examined the 
association between body temperature and outcome in 
patients with various bacterial infections, including 
pneumonia [27], spontaneous bacterial peritonitis [28], 
and Gram-negative bacteremia [29]. Th ese studies show 
that the absence of fever is a sign of poor prognosis in 
patients with bacterial infections. Overall, the design of 
these studies does not allow one to distinguish between 
the absence of fever as a marked of disease severity or 
impaired host resilience rather than the presence of fever 
as a protective response.
Fever in ICU patients with infections
Observational studies of fever and fever management in ICU 
patients
Th e epidemiology of fever in ICU patients and the 
frequency and utility of antipyretic use in ICU patients 
has been evaluated in a number of observational studies. 
Th e most important of the studies are summarized in 
Table 1.
Th e incidence of fever attributable to infection in 
observational studies in various critical care settings 
Table 1 Summary of key observational studies of fever and fever management in ICU patients
 Design, setting, and participants Key fi ndings
Laupland et al. 2008 [30] Retrospective cohort study of patients admitted to 
four ICUs in Calgary between 2000 and 2006; 
n = 24,204 ICU admissions in 20,466 patients
• Fever of ≥ 38.3 °C developed during 44 % of ICU admissions and 
high fever ≥ 39.3 °C during 8 % of admissions
• Fever was not associated with increased ICU mortality but high 
fever was associated with a signifi cantly increased risk of death
Young et al. 2011 [31] Inception cohort study in three tertiary ICUs in 
Australia and New Zealand over six weeks in 2010 
identifying patients with fever ≥ 38 °C and known or 
suspected infection; n = 565
• 9 % of patients admitted to ICU had or developed a fever and 
known or suspected infection
• Paracetamol was administered to about 2/3 of patients with fever 
and known or suspected infection on any given day 
Selladurai et al. 2011 [32] Retrospective cohort study of patients admitted to 
a single tertiary ICU in Australia with sepsis between 
December 2009 and August 2010; n = 106
• 69 % of septic patients received paracetamol at least once 
during their fi rst seven days in ICU
• 88 % of septic patients with a fever > 38 °C received 
paracetamol during their fi rst seven days in ICU
• Septic patients with a fever > 38 °C were 6.8 times (95 % CI 
1.9-24.7) more likely to receive paracetamol than septic patients 
who were not febrile
Lee et al. 2012 [33] Inception cohort study of consecutive patients 
admitted to 25 ICUs in Japan and Korea for more 
than 48 hours over three months in 2009; n = 1,425
• NSAID use independently associated with increased 28-day 
mortality in patients with sepsis (adjusted OR 2.61; 95 % CI 
1.11-6.11; p = 0.03) but with a trend towards a decreased 28-day 
mortality in patients without sepsis (adjusted OR 0.22; 95 % 0.03-
1.74; p = 0.15)
• Paracetamol use independently associated with increased 
28-day mortality in patients with sepsis (adjusted OR 2.05; 95 % 
CI 1.19-3.55; p = 0.01) but with a trend towards a decreased 28-
day mortality in patients without sepsis (adjusted OR 0.58; 95 % 
0.06-5.26; p = 0.63)
Laupland et al. 2012 [34] Inception cohort study of patients admitted to 
French ICUs contributing to the Outcomerea 
database between April 2000 and November 2010; 
n = 10,962
• 25.7 % of patients had a fever of ≥ 38.3 °C at ICU presentation
• Fever was not associated with increased mortality but 
hypothermia was an independent predictor of death in medical 
patients
Young et al. 2012 [35] Retrospective cohort study of 636,051 patients in 
Australia, New Zealand and the UK admitted to the 
ICU between 2005 until 2009
• Elevated body temperature in the fi rst 24 hours in ICU was 
associated with an increased risk of mortality in patients without 
infections and a decreased risk of mortality in patients with 
infections
Niven et al. 2012 [36] Interrupted time series analysis of cumulative fever 
incidence in ICUs in Calgary from 2004–2009
• The cumulative incidence of fever ≥ 38.3 during ICU admission 
decreased from 50.1 % to 25.5 % over the 5.5 years of the study
CI: confi dence interval; ICU: intensive care unit; NSAIDs: non-steroidal anti-infl ammatory drugs; OR: odds ratio
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varies from 8 % to 37 % [31], [34], [36]–[41]. Th ese 
studies use a variety of deﬁ nitions of fever and a range of 
methods to record temperature, making comparisons 
between studies diﬃ  cult. In these studies, the presence of 
fever was associated with either an increased risk of 
death [30], [39]–[41] or no diﬀ erence in mortality risk 
compared to a normal temperature [34]. Only two studies 
have evaluated the mortality risk of patients with sepsis 
separately from patients without sepsis [33], [35]. In the 
ﬁ rst study, fever was associated with an increased 28-day 
mortality risk in patients without sepsis but not in 
patients with sepsis [33] raising the possibility that the 
presence of infection might be an important determinant 
of the signiﬁ cance of the febrile response in ICU patients. 
Similarly, in a retrospective cohort study [35] 
(n  =  636,051) using two independent, multicenter, 
geographically distinct and representative databases we 
found that peak temperatures above 39.0 °C in the ﬁ rst 
24 hours after ICU admission were generally associated 
with a reduced risk of in-hospital mortality in patients 
with an admission diagnosis of infection. Conversely, 
higher peak temperatures were associated with an 
increased risk of in-hospital mortality in patients with a 
non-infection diagnosis.
Overall, although one recent study suggests that the 
incidence of fever is decreasing over time [36], existing 
observational data suggest that fever is a commonly 
encountered abnormal physical sign in ICU patients. 
Unfortunately, because of the potential for unmeasured 
confounding factors, it is impossible to establish whether 
treating fever in ICU patients with an infection is beneﬁ cial 
or harmful on the basis of observational studies.
Interventional studies of fever management in ICU patients
Two recently published meta-analyses found no evidence 
that antipyretic therapy was either beneﬁ cial or harmful 
in non-neurologically injured ICU patients [2], [3]. 
Nearly all of the patients included in these meta-analyses 
had known or suspected sepsis and one of the meta-
analyses only included patients with infection [3]. In both 
meta-analyses, the authors noted that existing studies 
lacked adequate statistical power to detect clinically 
important diﬀ erences and recommended that large 
randomized controlled trials were urgently needed. Th e 
details of published interventional studies of fever 
management strategies in ICU patients are summarized 
in Table 2.
Th e largest published randomized controlled trial 
evaluated the use of ibuprofen in critically ill patients 
with sepsis [43]. Patients with severe sepsis were 
randomized to receive 10 mg/kg of ibuprofen or placebo 
every six hours for a total of eight doses. Although the 
use of ibuprofen signiﬁ cantly reduced body temperature, 
it did not alter 30-day mortality, which was 37 % in the 
ibuprofen-treated group and 40 % in the placebo group. 
Th is study was designed to evaluate the use of ibuprofen 
as an anti-inﬂ ammatory rather than as an anti-pyretic 
and, while the use of ibuprofen signiﬁ cantly reduced 
temperature compared to placebo, the study included 
patients who were hypothermic as well as patients who 
were febrile. An additional confounding factor was that 
patients assigned to the ibuprofen group were treated 
with paracetamol more often than those assigned to the 
control group. On the basis of this [43] and other smaller 
studies [45], [46] of non-steroidal anti-inﬂ ammatory 
drugs (NSAIDs) in critically ill patients, it is clear that 
NSAIDs are eﬀ ective at reducing temperature in febrile 
ICU patients. However, there is no consistent mortality 
signal from the existing studies of NSAIDs. Some studies 
show trends towards beneﬁ t [42]–[44] with the use of 
NSAIDs and others show trends towards harm [45], [46].
Th e second largest published study of temperature 
management in febrile ICU patients evaluated the use of 
external cooling [49]. Th is study randomized 200 febrile 
patients with septic shock requiring vasopressors, 
mechanical ventilation, and sedation to external cooling 
to normothermia (36.5-37 °C) for 48 hours or no external 
cooling. Th e primary endpoint was the proportion of 
patients with a 50  % decrease in vasopressor use at 
48  hours after randomization. Th ere was no signiﬁ cant 
diﬀ erence between the treatment groups for the primary 
endpoint, which was achieved in 72  % of the patients 
assigned to external cooling and 61  % of the patients 
assigned to standard care. Th is study had a large number 
of secondary endpoints including mean body tempera-
ture, the proportion of patients who achieved 50  % 
reduction in vasopressors at 2 hours, 12 hours, 24 hours, 
and 36  hours as well as day-14, ICU, and hospital 
mortality. Th e secondary endpoints generally favored 
external cooling and day-14 mortality was noted to be 
signiﬁ cantly lower in the external cooling group (19 % vs. 
34  %; p  =  0.0013). Th is diﬀ erence in mortality was not 
evident by the time of ICU or hospital discharge and 
caution should be exerted in interpreting these endpoints 
as it is possible that they were aﬀ ected by a type 1 error 
due to a lack of statistical power.
Another trial compared temperature control strategies 
in a tertiary trauma ICU and randomized patients to 
either aggressive temperature control or a permissive 
strategy [47]. Patients assigned to the aggressive 
treatment arm received regular paracetamol once the 
temperature exceeded 38.5  °C and physical cooling was 
added when the temperature exceeded 39.5  °C. Patients 
assigned to the permissive treatment arm received 
paracetamol and cooling when the temperature reached 
40  °C. Th is trial originally aimed to enroll 672 patients; 
however, it was stopped by the Data Safety Monitoring 
Board after enrolment of 82 patients due to a trend 
Young and Saxena Critical Care 2014, 18:206 
http://ccforum.com/content/18/2/206
Page 5 of 8
towards increased mortality in the aggressive treatment 
group. While all deaths were attributed to septic causes, 
conventional stopping rules were not used and 
diﬀ erences between the study treatment arms could be 
due to chance. Th is study had other major limitations 
including a lack of blinding or placebo-control, and 
potential confounding from the uncontrolled use of other 
antipyretic drugs and per-protocol use of external 
cooling. A similar open-label randomized study enrolled 
26 febrile ICU patients and assigned them to aggressive 
or permissive temperature management [48]. In this 
study, the aggressive fever control group received 
paracetamol 650 mg enterally every 6  hours when the 
temperature was ≥ 38.3 °C and received physical cooling 
for temperature ≥ 39.5 °C. Th e permissive group did not 
receive paracetamol until the temperature was ≥ 40 °C 
and did not receive physical cooling until the temperature 
reached ≥  40.5  °C. All patients assigned to aggressive 
temperature management had an infectious etiology of 
fever and 75  % of patients assigned to the permissive 
management arm had an infectious etiology at baseline. 
Th e 28-day all cause mortality was not signiﬁ cantly 
diﬀ erent between the two groups.
Th e safety and eﬃ  cacy of using paracetamol to treat 
fever in ICU patients with infections is being evaluated in 
a 700-patient phase IIb, multicenter, randomized 
placebo-controlled trial (the HEAT trial), which is due to 
complete enrolment in November 2014 [50].
Table 2 Summary of randomized controlled trials investigating the management of fever in critically ill adults
 Design, setting, and participants Key fi ndings
Bernard et al. 1991 [42] Double blind placebo-controlled trial of ibuprofen in 
patients with severe sepsis; n = 30
• Ibuprofen signifi cantly reduced temperature, heart rate, and 
peak airway pressure
• There was no signifi cant diff erence between ibuprofen and 
placebo in terms of in-hospital mortality rate (18.8 % ibuprofen-
treated group vs. 42.9 % placebo-treated group)
Bernard et al. 1997 [43] Double blind placebo-controlled trial of ibuprofen in 
patients with severe sepsis in seven centers in North 
America; n = 455
• Ibuprofen signifi cantly reduced temperature, heart rate, oxygen 
consumption, and lactic acidosis in patients with severe sepsis
• Ibuprofen did not alter the incidence or duration of shock or 
ARDS and had no signifi cant eff ect on 30-day mortality (37 % 
ibuprofen-treated group vs. 40 % placebo-treated group)
Memis et al. 2004 [44] Double blind placebo-controlled trial of lornoxicam 
in patients with severe sepsis in one center in Turkey; 
n = 40
• No signifi cant diff erence between lornoxicam and placebo 
was demonstrated in terms of hemodynamic parameters, 
biochemical parameters, cytokine levels, or ICU mortality (35 % 
lornoxicam-treated group vs. 40 % placebo-treated group)
Morris et al. 2011 [45] Multicenter, randomized trial comparing the 
antipyretic effi  cacy of a single dose of placebo, 
100 mg, 200 mg, or 400 mg of i. v. ibuprofen in 
hospitalized patients of whom > 90 % had infections; 
n = 120 (53 critically ill)
• All doses of ibuprofen tested were eff ective in lowering 
temperature
• There were no signifi cant diff erence between treatment groups 
with respect to ventilation requirements, length of stay or 
in-hospital mortality (4 % placebo, 3 % 100 mg ibuprofen, 7 % 
200 mg ibuprofen, 6 % 400 mg ibuprofen)
Haupt et al. 1991 [46] Multicenter, placebo-controlled randomized trial of 
ibuprofen in patients with severe sepsis; n = 29
• Ibuprofen signifi cantly reduced body temperature
• There was no signifi cant diff erence between the treatment 
groups in terms of in-hospital mortality (30.8 % in the placebo 
group vs. 56.3 % in the ibuprofen group)
Schulman et al. 2006 [47] Single center, unblinded, randomized trial of 
aggressive vs. permissive temperature management 
in febrile patients in a trauma ICU; n = 82
• There was no signifi cant diff erence between the treatment arms 
in terms of the number of new infections
• The in-hospital mortality was 15.9 % in the aggressive treatment 
group and 2.6 % in the permissive treatment group (p = 0.06)
Niven et al. 2012 [48] Multicenter, unblinded randomized trial of 
aggressive vs. permissive temperature management 
in febrile ICU patients; n = 26
• The mean daily temperature was lower in the patients assigned 
to aggressive fever management
• The in-hospital mortality was 21 % in the aggressive treatment 
group and 17 % in the permissive treatment group (p = 1.0)
Schortgen et al. 2012 [49] Multicenter, randomized controlled trial of external 
cooling in patients with fever and septic shock 
receiving mechanical ventilation in seven centers in 
France; n = 200
• External cooling signifi cantly reduced body temperature
• External cooling did not alter the proportion of patients who 
had a 50 % reduction in vasopressor dose after 48 hours
• Day-14 mortality was signifi cantly lower in the patients assigned 
to external cooling but there was no signifi cant diff erence 
between the groups in terms of ICU or in-hospital mortality
ARDS: acute respiratory distress syndrome; ICU: intensive care unit.
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Conclusion
Th ere is a signiﬁ cant body of animal data demonstrating 
that fever is an important component of the host 
response to infection and confers a survival advantage in 
a number of animal species. Th e conservation of a 
metabolically costly response across a broad range of 
animal species suggests that the response probably has an 
evolutionary advantage. Th ere are some interesting 
historical examples of hyperthermia being employed to 
treat infectious diseases. However, in the modern era the 
relevance of these examples is questionable. Furthermore, 
arguments based on the evolutionary importance of the 
febrile response do not necessarily apply to critically ill 
patients who are, by deﬁ nition, supported beyond the 
limits of normal physiological homeostasis. Humans are 
not adapted to critical illness. In the absence of modern 
medicine and intensive care, most critically ill patients 
with fever and infection would presumably die. Among 
critically ill patients, it is biologically plausible that there 
is a balance to be struck between the potential beneﬁ ts of 
reducing metabolic rate that come with fever control and 
the potential risks of a deleterious eﬀ ect on host defense 
mechanisms. Remarkably, at present, we do not know 
what eﬀ ect treating fever in critically ill patients with 
infections has on patient-centered outcomes. Th ese 
treatments include commonly used interventions such as 
paracetamol and physical cooling. Th is area of research is 
of high priority given the global epidemiology of fever in 
critically ill patients and the generalizability of the 
candidate interventions.
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